Floatz logo

msc1936369b

Metastatic Melanoma

M.D. Anderson Cancer CenterPhase 1/2Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

104 Active assets in the Metastatic Melanoma cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 2BBB
DACARBAZINE
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Therapeutic Autologous Lymphocytes
Fred Hutchinson Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

msc1936369b is also rated in:

cutaneous melanomaDormant
CCC
Indicative ·
52 / 100
View asset →
breast cancerDormant
CC
Indicative ·
46 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →